Integration of cancer stemness and neoantigen load to predict responsiveness to anti-PD1/PDL1 therapy

Background: Anti-programmed cell death 1/programmed cell death ligand 1 (PD1/PDL1) therapy is an important part of comprehensive cancer therapy. However, many patients suffer from non-response to therapy. Tumor neoantigen burden (TNB) and cancer stemness play essential roles in the responsiveness to...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Kunpeng, Liu, Shuqiang, Shen, Xiuyun, Xu, Jincheng, Shi, Chunpeng, Chao, Yuqiu, Wen, Zhengchao, Zhang, Kejiao, Wang, Ru, Liu, Bing, Jiang, Yanan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714307/
https://www.ncbi.nlm.nih.gov/pubmed/36467413
http://dx.doi.org/10.3389/fcell.2022.1003656

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714307/
https://www.ncbi.nlm.nih.gov/pubmed/36467413
http://dx.doi.org/10.3389/fcell.2022.1003656

Ejemplares similares